EGFR and colorectal carcinoma: Accordingly, the combination treatment of pp242 and erlotinib, an EGFR inhibitor, completely blocked both mTORC1 and mTORC2 activity, inhibited cell growth and suppressed the progression of CRC xenografts [129].